(Reuters) - The Swiss drugmaker earlier on Thursday reported stronger- than-expected second-quarter Tamiflu sales of $369 million as pandemic sales more than offset minimal seasonal flu sales.
"This translates into approximately $77 million in royalty revenue to Gilead in the third quarter of 2007, 26 percent higher than our estimate of $61 million," Jefferies & Co. analyst Eun Yang wrote in a research note.
Read more at Reuters.com Hot Stocks News
"This translates into approximately $77 million in royalty revenue to Gilead in the third quarter of 2007, 26 percent higher than our estimate of $61 million," Jefferies & Co. analyst Eun Yang wrote in a research note.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment